Alterity Therapeutics to Present New Data at the Upcoming :

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to...

Related Keywords

Colorado , United States , San Francisco , California , Melbourne , Victoria , Australia , Denver , Americans , American , Danielo Claassen , Remy Bernarda , Hannah Howlett , Daniel Claassen , Margaret Bradbury , David Stamler , European Commission , Vanderbilt University , National Institute Of Health , Parkinson Foundation , American Academy Of Neurology , Alterity Therapeutics , International Conference , Vanderbilt University Medical Center , Nasdaq , Nonclinical Development , Positive Efficacy Data , Primate Model , Baseline Biomarker Data , American Academy , Chief Executive Officer , Novel Inhibitor , Synuclein Aggregation , Multiple System Atrophy , Plight Chain , Clinical Progression , Early Multiple System , Vanderbilt University Medical , Clinical Phase Small Molecule , Moderate Affinity , Disease Model , Vice President , System Atrophy , Neurological Disorders , Disease Information Page , Multiple System , Media Contacts , Securities Act , Australian Stock Exchange Ath Ax , Alterity Therapeutics Limited , Eurology , Preclinical Research ,